Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Recommendation of "Buy" by Brokerages

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) have received a consensus recommendation of "Buy" from the seven analysts that are currently covering the company, Marketbeat.com reports. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $29.00.

DAWN has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $36.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, April 3rd. Wedbush restated an "outperform" rating and issued a $25.00 target price on shares of Day One Biopharmaceuticals in a research note on Wednesday, May 7th. Needham & Company LLC decreased their price objective on shares of Day One Biopharmaceuticals from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Finally, The Goldman Sachs Group decreased their price objective on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating on the stock in a report on Tuesday, March 25th.

Insider Activity

In other Day One Biopharmaceuticals news, General Counsel Adam Dubow sold 4,552 shares of the stock in a transaction on Friday, May 16th. The shares were sold at an average price of $6.26, for a total transaction of $28,495.52. Following the transaction, the general counsel directly owned 47,136 shares in the company, valued at $295,071.36. This represents a 8.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Charles N. York II sold 4,282 shares of the stock in a transaction on Friday, May 16th. The shares were sold at an average price of $6.26, for a total transaction of $26,805.32. Following the transaction, the chief financial officer owned 265,231 shares in the company, valued at $1,660,346.06. This trade represents a 1.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 26,725 shares of company stock valued at $167,299 over the last 90 days. Insiders own 6.20% of the company's stock.

Institutional Trading of Day One Biopharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the business. Virtus ETF Advisers LLC increased its holdings in shares of Day One Biopharmaceuticals by 7.1% in the 4th quarter. Virtus ETF Advisers LLC now owns 27,296 shares of the company's stock worth $346,000 after acquiring an additional 1,805 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Day One Biopharmaceuticals by 5.6% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,843 shares of the company's stock valued at $454,000 after purchasing an additional 1,894 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Day One Biopharmaceuticals during the 4th quarter valued at about $27,000. Exchange Traded Concepts LLC boosted its holdings in shares of Day One Biopharmaceuticals by 19.6% in the first quarter. Exchange Traded Concepts LLC now owns 14,693 shares of the company's stock worth $117,000 after buying an additional 2,407 shares during the period. Finally, Optimize Financial Inc boosted its holdings in shares of Day One Biopharmaceuticals by 16.0% in the first quarter. Optimize Financial Inc now owns 17,960 shares of the company's stock worth $142,000 after buying an additional 2,473 shares during the period. 87.95% of the stock is owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Stock Up 2.7%

Shares of DAWN opened at $7.19 on Friday. Day One Biopharmaceuticals has a fifty-two week low of $6.08 and a fifty-two week high of $16.76. The firm's 50 day moving average price is $6.64 and its 200 day moving average price is $8.87. The company has a market cap of $728.78 million, a P/E ratio of -10.13 and a beta of -1.27.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.35) EPS for the quarter, beating analysts' consensus estimates of ($0.46) by $0.11. Day One Biopharmaceuticals had a negative net margin of 42.66% and a negative return on equity of 14.98%. The company had revenue of $30.76 million for the quarter, compared to the consensus estimate of $30.28 million. Research analysts forecast that Day One Biopharmaceuticals will post -0.72 earnings per share for the current year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.